Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation

R. Chirinos Guevara (barcelona, Spain), E. Vélez (barcelona, Spain), C. Berastegui (barcelona, Spain), A. Villar (barcelona, Spain), E. Revilla (barcelona, Spain), H. Sintes (barcelona, Spain), B. Sáez (barcelona, Spain), M. López Meseguer (barcelona, Spain), C. Bravo (barcelona, Spain), V. Monforte (barcelona, Spain), A. Roman (barcelona, Spain), I. Bello (barcelona, Spain), J. Sacanell (barcelona, Spain)

Source: International Congress 2018 – Moving lung transplantation forward
Session: Moving lung transplantation forward
Session type: Thematic Poster
Number: 2586
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Chirinos Guevara (barcelona, Spain), E. Vélez (barcelona, Spain), C. Berastegui (barcelona, Spain), A. Villar (barcelona, Spain), E. Revilla (barcelona, Spain), H. Sintes (barcelona, Spain), B. Sáez (barcelona, Spain), M. López Meseguer (barcelona, Spain), C. Bravo (barcelona, Spain), V. Monforte (barcelona, Spain), A. Roman (barcelona, Spain), I. Bello (barcelona, Spain), J. Sacanell (barcelona, Spain). Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation. 2586

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: